Precision BioSciences Q2 net loss widens to $32.65 million; revenue drops to no revenue
DTIL•Quarterly results
- Precision BioSciences posted a net loss of USD 32.65 million for the quarter ended June 30, 2026, widening from USD 23.52 million a year earlier.
- Operating loss narrowed to USD 19.16 million from USD 21.88 million, while total operating expenses fell to USD 19.16 million from USD 21.9 million.
- Revenue was no revenue versus USD 18,000 a year earlier; research and development costs edged down to USD 12.39 million from USD 12.77 million.
- General and administrative expense dropped to USD 6.77 million from USD 9.13 million; a USD 13.89 million warrant-liability fair-value loss swung results versus a USD 753,000 gain.
Liquidity and outlook
- Cash, cash equivalents and restricted cash totaled USD 112.4 million at June 30, 2026.
- Management expects funding runway through with operating discipline and an .
